Yuhan Corp. (000100) - Total Assets
Based on the latest financial reports, Yuhan Corp. (000100) holds total assets worth ₩3.22 Trillion KRW (≈ $2.18 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Yuhan Corp. - Total Assets Trend (2000–2025)
This chart illustrates how Yuhan Corp.'s total assets have evolved over time, based on quarterly financial data. Also see market cap of Yuhan Corp. for the company's overall valuation and market capitalisation.
Yuhan Corp. - Asset Composition Analysis
Current Asset Composition (December 2025)
Yuhan Corp.'s total assets of ₩3.22 Trillion consist of 46.9% current assets and 53.1% non-current assets. Review Yuhan Corp. balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 10.8% |
| Accounts Receivable | ₩694.44 Billion | 21.6% |
| Inventory | ₩372.76 Billion | 11.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩184.67 Billion | 5.7% |
| Goodwill | ₩115.07 Billion | 3.6% |
Asset Composition Trend (2000–2025)
This chart illustrates how Yuhan Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Yuhan Corp. (000100) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yuhan Corp.'s current assets represent 46.9% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 10.8% of total assets in 2025, up from 5.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 21.6% of total assets.
Yuhan Corp. Competitors by Total Assets
Key competitors of Yuhan Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Yuhan Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.06 | 2.20 | 2.71 |
| Quick Ratio | 1.55 | 1.64 | 2.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩778.08 Billion | ₩741.12 Billion | ₩807.20 Billion |
Yuhan Corp. - Advanced Valuation Insights
This section examines the relationship between Yuhan Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 9.5% |
| Total Assets | ₩3.22 Trillion |
| Market Capitalization | $3.96 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Yuhan Corp.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Yuhan Corp.'s assets grew by 9.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Yuhan Corp. (2000–2025)
The table below shows the annual total assets of Yuhan Corp. from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩3.22 Trillion ≈ $2.18 Billion |
+9.48% |
| 2024-12-31 | ₩2.94 Trillion ≈ $1.99 Billion |
+4.61% |
| 2023-12-31 | ₩2.81 Trillion ≈ $1.91 Billion |
+13.73% |
| 2022-12-31 | ₩2.47 Trillion ≈ $1.68 Billion |
+0.36% |
| 2021-12-31 | ₩2.46 Trillion ≈ $1.67 Billion |
+2.94% |
| 2020-12-31 | ₩2.39 Trillion ≈ $1.62 Billion |
+13.05% |
| 2019-12-31 | ₩2.12 Trillion ≈ $1.43 Billion |
-2.60% |
| 2018-12-31 | ₩2.17 Trillion ≈ $1.47 Billion |
+3.78% |
| 2017-12-31 | ₩2.09 Trillion ≈ $1.42 Billion |
+2.38% |
| 2016-12-31 | ₩2.05 Trillion ≈ $1.39 Billion |
+8.81% |
| 2015-12-31 | ₩1.88 Trillion ≈ $1.27 Billion |
+16.36% |
| 2014-12-31 | ₩1.62 Trillion ≈ $1.10 Billion |
+6.74% |
| 2013-12-31 | ₩1.51 Trillion ≈ $1.03 Billion |
+7.90% |
| 2012-12-31 | ₩1.40 Trillion ≈ $950.85 Million |
+6.77% |
| 2011-12-31 | ₩1.31 Trillion ≈ $890.52 Million |
+4.66% |
| 2010-12-31 | ₩1.26 Trillion ≈ $850.84 Million |
+10.64% |
| 2009-12-31 | ₩1.13 Trillion ≈ $769.03 Million |
+9.23% |
| 2008-12-31 | ₩1.04 Trillion ≈ $704.04 Million |
+4.18% |
| 2007-12-31 | ₩997.19 Billion ≈ $675.78 Million |
+5.93% |
| 2006-12-31 | ₩941.40 Billion ≈ $637.97 Million |
+4.76% |
| 2005-12-31 | ₩898.67 Billion ≈ $609.01 Million |
+17.49% |
| 2004-12-31 | ₩764.90 Billion ≈ $518.36 Million |
+15.97% |
| 2003-12-31 | ₩659.58 Billion ≈ $446.99 Million |
+4.52% |
| 2002-12-31 | ₩631.04 Billion ≈ $427.64 Million |
+8.10% |
| 2001-12-31 | ₩583.76 Billion ≈ $395.60 Million |
+4.97% |
| 2000-12-31 | ₩556.14 Billion ≈ $376.89 Million |
-- |
About Yuhan Corp.
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and ana… Read more